Crizotinib
| Code | Size | Price |
|---|
| CDX-C0699-M010 | 10 mg | £108.00 |
Quantity:
| CDX-C0699-M050 | 50 mg | £304.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short Term: +20°C, Long Term: +4°C
Documents
Further Information
Alternate Names/Synonyms:
(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; PF 2341066; PF-02341066; PF02341066; Xalkori
Appearance:
White to off-white powder.
CAS:
877399-52-5
Class:
9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07,GHS08,GHS09
Handling Advice:
Protect from light and moisture.
Hazards:
H317-H319-H341-H400
InChi:
InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
InChiKey:
KTEIFNKAUNYNJU-GFCCVEGCSA-N
Long Description:
Chemical. CAS: 877399-52-5. Formula: C21H22Cl2FN5O. MW: 450.34. Synthetic. Crizotinib is an anticancer drug. It is a potent, orally bioavailable, ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor), anaplastic lymphoma kinase (ALK) and ROS1 (c-ros oncogene 1). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.
MDL:
MFCD12407409
Molecular Formula:
C21H22Cl2FN5O
Molecular Weight:
450.34
Package Type:
Vial
PG:
III
Precautions:
P273-P280-P305 + P351 + P338
Product Description:
Crizotinib is an anticancer drug. It is a potent, orally bioavailable, ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor), anaplastic lymphoma kinase (ALK) and ROS1 (c-ros oncogene 1). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@H](C)C4=C(Cl)C(F)=CC=C4Cl
Solubility Chemicals:
Soluble in choroform, DMSO or methanol.
Source / Host:
Synthetic
Transportation:
Excepted Quantity
UN Nummer:
3077
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
(1) H.Y. Zou, et al.; Cancer Res. 67, 4408 (2007) | (2) J.G. Christensen, et al.; Mol. Cancer Ther. 6, 3314 (2007) | (3) J.J. Cui, et al.; J. Med. Chem. 54, 6342 (2011) | (4) J. Tanizaki, et al.; J. Thorac. Oncol. 6, 1624 (2011) | (5) Y. Yuan, et al.; J. Hematol. Oncol. 4, 1 (2011) | (6) A.T. Shaw, et al.; N. Engl. J. Med. 371, 1963 (2014)